Last reviewed · How we verify
IONIS-STAT3Rx
At a glance
| Generic name | IONIS-STAT3Rx |
|---|---|
| Also known as | ISIS 481464 |
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IONIS-STAT3Rx CI brief — competitive landscape report
- IONIS-STAT3Rx updates RSS · CI watch RSS
- Ionis Pharmaceuticals, Inc. portfolio CI